debrisan
Dextranomer is a cicatrizant used in dressings for wound healing, and in pharmaceutical products to treat fecal incontinence. It consists of dextran polymer chains cross-linked into a three-dimensional network. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Oct 1, 2014 (NCT02271035)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
- Unspecified targetOTHER
Unknown
Dextranomer exerts its effect by a capillary action which absorbs wound exudate, as well as wound debris and microorganisms, into the dextranomer beads or into the spaces between the beads, thus removing such products from the wound surface. Dextranomer is an aid to wound or ulcer management, and does not directly affect tissue repair in such ulcers, but the removal of debris (and possibly microorganisms) from the wound could be expected to promote natural healing.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDextranomer ↗
- ChEMBLCHEMBL2108201 ↗
Also known as
- acudex
- debrisan
- debrisan
- debrizan
- deshisan
- deskhizan
- dextran, 2,3-dihydroxypropyl 2-hydroxy-1,3-propanediyl ether
- dextranomer
- dextranomer
- dextranomer
- envisan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02271035 | Phase 4 | Oct 1, 2014 | Tel Aviv University |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tel Aviv University | Academic/Hospital | 1 | 1 | 1 | 2014 |